title: Cardiovascular changes after treatment with dexfenfluramine and yohimbine in obese women measured by thoracic electrical bioimpedance.
abstract: An anorectic drug, dexfenfluramine (dF) is commonly used in obesity treatment. The aim of our study was to investigate if dexfenfluramine used alone or together with alpha 2-adrenolitic yohimbine (Y), can change cardiovascular state in obese women.
authors.affiliation: Department of Gastroenterology, Silesian Medical Academy, Katowice, Poland.
authors.forename: M
authors.initials: M
authors.lastname: Waluga
authors.forename: M
authors.initials: M
authors.lastname: Janusz
authors.forename: E
authors.initials: E
authors.lastname: Karpel
authors.forename: M
authors.initials: M
authors.lastname: Hartleb
authors.forename: A
authors.initials: A
authors.lastname: Nowak
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D001067:Appetite Depressants / Q000009:adverse effects* / Q000627:therapeutic use; D020372:Dexfenfluramine / Q000009:adverse effects* / Q000627:therapeutic use; D017097:Electric Impedance; D005080:Exercise Test; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D009765:Obesity / Q000188:drug therapy / Q000503:physiopathology*; D015016:Yohimbine / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000317:Adrenergic alpha-Antagonists; D001067:Appetite Depressants; D015016:Yohimbine; D020372:Dexfenfluramine